logo

Seres Therapeutics, Inc. (MCRB)



Trade MCRB now with
  Date
  Headline
9/15/2021 7:07:05 AM Seres Therapeutics Enrolls 300 Subjects With Phase 3 ECOSPOR IV Open-Label Extension Study Of SER-109
8/3/2021 7:27:29 AM Seres Therapeutics Q2 Net Loss $48.3 Mln Vs. Net Loss Of $20.7 Mln Prior Year
7/1/2021 7:09:35 AM Seres Therapeutics, Nestl Health Science Unveil SER-109 Co-Commercialization License Deal
5/19/2021 9:45:37 AM Invaio Sciences Announces Agreement With Fundecitrus In Brazil To Combat Against Citrus Greening
5/4/2021 7:25:53 AM Seres Therapeutics Q1 Loss Per Share $0.39 Vs Loss $0.28 Last Year
3/8/2021 7:15:56 AM Seres Therapeutics Reports Discontinuation Of Enrollment In SER-401 Study In Metastatic Melanoma
3/2/2021 7:18:48 AM Seres Therapeutics Q4 Net Loss $18.3 Mln Vs. Net Loss $18.8 Mln Last Year
1/6/2021 7:17:43 AM Seres Therapeutics Publishes Positive SER-287 Phase 1b Ulcerative Colitis Study Results In Journal Gastroenterology
11/9/2020 7:16:26 AM Seres Therapeutics Q3 Loss Per Share $0.36 Vs Loss $0.23 Last Year
10/22/2020 7:26:23 AM Seres Therapeutics Names David Ege EVP, CTO And Jayne Gansler As EVP And CPO
9/11/2020 7:09:06 AM Seres Therapeutics Obtains Correspondence From FDA Following Positive SER-109 Phase 3 Study Results
8/12/2020 10:07:49 PM Seres Therapeutics Prices Underwritten Public Offering Of 10.50 Mln Shares At $21.50/shr
6/22/2020 7:05:21 AM Seres Therapeutics Appoints Terri Young As EVP, Chief Commercial And Strategy Officer